Catherine T. Doherty - Nov 29, 2021 Form 4 Insider Report for QUEST DIAGNOSTICS INC (DGX)

Signature
/s/ William J. O'Shaughnessy, Jr., Attorney in Fact for Catherine T. Doherty
Stock symbol
DGX
Transactions as of
Nov 29, 2021
Transactions value $
-$5,890,575
Form type
4
Date filed
12/1/2021, 03:34 PM
Previous filing
May 11, 2021
Next filing
Feb 25, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DGX Common Stock Options Exercise $3.6M +37.6K +54.66% $95.80 106K Nov 29, 2021 Direct F1
transaction DGX Common Stock Sale -$46K -300 -0.28% $153.38 106K Nov 29, 2021 Direct F1, F2
transaction DGX Common Stock Sale -$503K -3.25K -3.07% $154.79 103K Nov 29, 2021 Direct F1, F3
transaction DGX Common Stock Sale -$550K -3.53K -3.44% $155.77 99.2K Nov 29, 2021 Direct F1, F4
transaction DGX Common Stock Sale -$2.5M -15.9K -16.03% $156.86 83.3K Nov 29, 2021 Direct F1, F5
transaction DGX Common Stock Sale -$2.3M -14.6K -17.5% $157.53 68.7K Nov 29, 2021 Direct F1, F6
holding DGX Common Stock 4.14K Nov 29, 2021 401(k)/SDCP F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DGX Non-Qualifed Stock Option (right to buy) Options Exercise -$3.6M -37.6K -100% $95.80 0 Nov 29, 2021 Common Stock 37.6K $95.80 Direct F1, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This exercise and sales reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on October 29, 2021.
F2 This transaction was executed in multiple trades at prices ranging from $153.21 to $153.49. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 This transaction was executed in multiple trades at prices ranging from $154.21 to $155.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4 This transaction was executed in multiple trades at prices ranging from $155.26 to $156.17. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5 This transaction was executed in multiple trades at prices ranging from $156.27 to $157.26. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6 This transaction was executed in multiple trades at prices ranging from $157.27 to $158.22. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7 These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date.
F8 The options vested in three annual installments beginning with the first on February 21, 2018, the second on February 21, 2019 and the final on February 21, 2020.